TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Peripheral lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of obtaining capture of HIS-bundle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Narrowing of the QRS-duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment-related Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and Tolerability of RJX as Assessed by Neurological Examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Total PANSS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global clinical impression of change from baseline at week 24
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Outcome of ACS patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Tumor Size of Treatment-targeted Surgically Eligible Basal Cell Carcinomas (SEBs) From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change in the Hedgehog (HH) Signaling Pathway Target Gene Glioma-associated Oncogene Homolog 1 (GLI1) Messenger Ribonucleic Acid (mRNA) Levels From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With a Treatment-emergent Adverse Event Causally Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Parental self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Child self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parental feeding practices/self-regulatory behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior Angle Width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Letter Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Evaluation of liver steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incidence of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Area under the plasma Factor VIII activity versus time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Primary Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Performance Primary Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor uptake of 89Zr-Avelumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of OPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal Tolerance Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Thickness of the duodenal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: total exposure and pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All cause of morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability based on vital signs and clinical assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Thrombus Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AUCinf of Cilofexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microhemorrhage (CMB) of T2* sequence in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Crisis line utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma concentrations of sufentanil and hydromorphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scale for Clinical Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients developing RAS mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: VO2 Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Prescribed OAC Drug
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Hypoxia-inducible Factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative iron bioavailability (RBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants in clinical groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With PASI100 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Dose Limiting Toxicities of Selinexor
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adverse Events of Selinexor
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Drug Concentration Curve of Selinexor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tryptophan turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor Response Type
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Assessment of tolerability by investigator on a 4-point scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with abnormal changes in clinical laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 6-month PFS (rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of contraction stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional status outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Puff topography of tobacco cigarette smoked
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malaria infection presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Exercise compliance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Stress consultation compliance rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Incidence of Pulmonary Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Patients Experiencing at Least 1 Solicited Local and/or Systemic Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: time to appropriate antibiotic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of symptom surveys completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent patients report satisfied
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean/median time to resolution of patient alerts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum tolerated dose (MTD) of Pazopanib and Vorinostat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of local control of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnosis capacity of molecular signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: s-P Levels of Less Than or Equal to 5.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of questionnaire completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Negative Symptom Changes - NSA-16 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative and postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Amount of Epogen Required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACL Clinical Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between QIM predicted and pathologically determined tumor class
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Agreement between QIM predicted and pathologically determined tumor grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Agreement between QIM predicted and clinically observed perioperative measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-carboplatin or Oxaliplatin Acute Hypersensitivity Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic yield of NMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: FEV1 post bronchodilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Psychosocial Adjustment to Illness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose of dasatinib
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Target Blood Pressure Goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-rating Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-rating Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Intubation Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety measured by Grade 3 to 5 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Any First Post-op Atrial Fibrillation or Flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sitting Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eventration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Hair loss
Endpoint domain: Adverse events/effects
Primary endpoint: OLFM4 rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: safety and efficacy of deferasirox
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caregiver anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximal percent weight loss compared to birth weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients who received red blood cells transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfusion volume of red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Acceptable Radiographic Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of different etiologies of acute pancreatitis (AP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Screening colonoscopy completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Biochemical verification of smoking status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Significant adverse event (SAE) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Changed frequency range in voice function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Joint Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Navicular Rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Intensity of fixation of the solvent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PARS Treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0 to Inf]) for GSK3640254-Part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) for GSK3640254-Part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Maximum Observed Concentration for GSK3640254-Part 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of health services
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: modified 5-point modified Ashworth scale (AS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Experience Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinue Study Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Prolapse measured by POP-Q
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving Serum 17-OHP Targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean decrease in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean decrease in blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean decrease in LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean decrease in cholesterol/HDL-ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of patients achieving glycaemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of reaction times in ms in a motor learning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of delayed memory scores in # of words in a Verbal learning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of performance in ms in a reaction time task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of relative regional grey matter volumes in %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient response to stent placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence or absence of height and width of the saccule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on Weight Bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful clearance rate of sodium bicarbonate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful clearance rate of alteplase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of UCB-MSC
Endpoint domain: Adverse events/effects
Primary endpoint: Awareness of social marketing campaign
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased positive outcome expectations for condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Serious Adverse Event(s) (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Malaria Control Interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Odds Ratio for the Number of Subjects With MCI, Infected With P. Falciparum Parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anti-TNF treatment response based on circulant rheumatoid factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-TNF treatment response based on circulant cyclic citrullinated anti-peptide antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of Frailty (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endurance time at High Altitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successfully located and removed implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: initial stone clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHO functional class change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Subcutaneous ecchymoses number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Subcutaneous hematomas number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: QoL-SF36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Family perception of Plumpy'Mum
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of ICU Stays Greater Than 1.5 Days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of emergence delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Cardiovascular Death, Myocardial Infarction, Stroke, Any Unplanned Repeat Revascularization, Bleeding, Severe Hypotension, and Change in Aortic Insufficiency
Endpoint domain: Mortality/survival
Primary endpoint: Change in Primary Ocular Discomfort (POD) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Algometer readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior Rating Inventory of Executive Function-Adult (BRIEF-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cambridge Neuropsychological Test Automated Battery (CANTAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of obstructive sleep apnea symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduced colonization routes from bronchial secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hemoglobin Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of subjects withdrawing due to serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse event assessments
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of acute gastrointestinal GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: acute VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: treatment with ECMO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of P-PSMA-101
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose of P-PSMA-101
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of P-PSMA-101 (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EORTC QLQ-C30 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in MAIA-C scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of complications observed intraoperatively through 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patient reported complications post 30-days through 3 years post procedure
Endpoint domain: Adverse events/effects
Primary endpoint: number of participants with post-surgical wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of diabetes remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of MAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation of Stroke Volume Variation (SVV) and Pleth Variability Index (PVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes